Specialist Updates 
Rheumatology

New febuxostat trial douses cardiovascular alarm

Investigators hope results from the FAST trial will lead to a rethink of boxed warnings on the drug
Medicom Staff writer
0
13 November 2020
Save
ClosePlease login

AusDoc brings you the latest news from the American College of Rheumatology virtual congress 2020.

Patients with gout who are treated with febuxostat are at no more increased risk of cardiovascular events or death than those taking allopurinol, European researchers have reported.

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Content that breaches the privacy of other individuals
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .